Fulvestrant en la práctica clínica: análisis de efectividad en pacientes uruguayas con cáncer de mama HR+/HER2
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Fulvestrant treatment for advanced hormone receptor-positive, HER2-negative breast cancer showed benefits in real-world practice. Survival outcomes were influenced by metastasis presence and patient performance status.
Area Of Science
- Oncology
- Clinical Pharmacology
- Epidemiology
Background
- Fulvestrant is a key treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer.
- Real-world data on fulvestrant efficacy in resource-limited settings is crucial for treatment optimization.
Purpose Of The Study
- To evaluate the efficacy of fulvestrant in HR+, HER2- advanced breast cancer patients within national treatment coverage protocols.
- To compare real-world outcomes with pivotal clinical trial data.
Main Methods
- Retrospective analysis of a National Resources Fund database (2009-2022).
- Kaplan-Meier method for survival analysis.
- Log-Rank test for comparing survival differences.
Main Results
- 1085 patients included, median overall survival (OS) of 16 months, median progression-free survival (PFS) of 6 months.
- Liver and bone metastases correlated with shorter OS.
- Public sector patients and those with better performance status had longer OS.
Conclusions
- Fulvestrant demonstrates clinical utility in real-world settings, though OS and PFS may be lower than in clinical trials.
- Metastasis and performance status are critical prognostic factors.
- Findings highlight the need for personalized treatment strategies in resource-constrained environments.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.